This trial will study the effectiveness, safety, and how the body processes a new drug for chronic hives.
1 Primary · 3 Secondary · Reporting Duration: From baseline to Day 85 (Week 12)
Experimental Treatment
168 Total Participants · 6 Treatment Groups
Primary Treatment: barzolvolimab · Has Placebo Group · Phase 2
Age 18+ · All Participants · 9 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: